Coinbase says Paul Grewal has stepped down as chief legal officer
Coinbase Global said Paul Grewal, its chief legal officer, notified the company that he will step down, leaving the crypto exchange to name a successor.
Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
Coinbase Global said Paul Grewal, its chief legal officer, notified the company that he will step down, leaving the crypto exchange to name a successor.
THE APEX TIMES
A fresh opening for Nvidia’s most advanced AI chips in China is drawing attention on Wall Street, yet the practical impact on revenue and supply timelines remains unclear from the latest reporting.
In a brief remark circulated by Yahoo Finance, JPMorgan CEO Jamie Dimon suggested investors should keep a close eye on how risks show up in real time, a theme that fits a market still digesting rate and credit uncertainty.
Stoxx 600 closes up marginally, while a separate report says Uber is nearing a potential deal for Delivery Hero, a move that could reshape Europe’s food-delivery and last-mile competition.
A market recap tied the day’s move in Palantir Technologies to reactions around its latest earnings, centering on free cash flow as the key follow-through investors want to see.
The two-day event on Sept. 17-18 pairs a first-ever creator video premiere at El Capitan with a creator-economy summit program at Walt Disney Studios, with attendance curated and applications accepted on a rolling basis.
In a blog post celebrating the 25th anniversary of Google Images, Alphabet’s Google said the visual search product has evolved from finding pictures to helping people explore and create visual content, while outlining a timeline of major milestones.
Alphabet’s Google says it will invest in and buy energy and battery storage output from the Steel River Energy Center, calling it its largest solar and battery storage project to date.
Investors are looking for signs that Pfizer’s oncology portfolio, including growth from its cancer medicines, biosimilars, and pipeline updates, can offset weakness in older treatments when the company reports second-quarter results.